Switzerland· 63042003

Giotrif

A afatinib product containing afatinibum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EB03

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedGiotrifATCL01EB03REGISTER NO.63042003PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Afatinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EB03 (afatinib), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Afatinib · ATC L01EB03

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of afatinib costs, country by country.

Normalised to the WHO defined daily dose (40 mg), so markets compare like for like.

  • Switzerland: $199.66 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Afatinib · price per daily dose (40 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$199.66
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
afatinibum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L01EB03
ATC class
Afatinib
Defined daily dose
40 mg, O
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680630420039
    28 Stk
    CHF 2318.15

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

170 interactions on record for afatinib.

Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Afatinib · interactions on record

170 records

  • 10 severe
  • 158 moderate
  • 2 minor

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • PexidartinibL01EX15severe
  • Aminolevulinic acidL01XD04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Afatinib in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All afatinib products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Cyprus · Afatinib Afatinib, Afatinib Sapiens
  • Greece · Webrix
  • Iceland · Giotrif
  • Liechtenstein · Giotrif
  • Latvia · Afatinib, Afatinib Lotus
  • Malta · Afatinib Lotus
  • Norway · Giotrif
  • Sweden · Afatinib Lotus, Webrix

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/14b345c6-5459-460e-befb-402b4f214afe
GET /v1/drugs/14b345c6-5459-460e-befb-402b4f214afe?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "afatinibum 40 mg",
  "valid_from": "2014-03-01",
  "limitations": "[{\"description\":\"Nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes, als Monotherapie für Patienten mit nicht-kleinzelligem Lungenkarzinom (NSCLC, Stadium IIIb/IV) mit aktivierenden Mutationen des EGFR (Exon 19 Deletionen oder Exon 21 L858R Substitutionen), die nicht mit EGFR-TKIs vorbehandelt sind.\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2014-03-01\",\"validTo\":null}]",
  "galenic_form": "Filmtabl 40 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2014-03-01",
  "self_retention_pct": 10
}

See everything about afatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.